Tiedemann Advisors LLC acquired a new stake in shares of Metlife Inc (NYSE:MET) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 7,072 shares of the financial services provider’s stock, valued at approximately $308,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Mount Yale Investment Advisors LLC acquired a new stake in Metlife during the 1st quarter valued at approximately $108,000. Kaizen Advisory LLC grew its stake in Metlife by 148.0% during the 2nd quarter. Kaizen Advisory LLC now owns 2,515 shares of the financial services provider’s stock valued at $110,000 after purchasing an additional 1,501 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in Metlife during the 2nd quarter valued at approximately $110,000. FNY Investment Advisers LLC acquired a new position in shares of Metlife in the 2nd quarter worth approximately $112,000. Finally, Adviser Investments LLC acquired a new position in shares of Metlife in the 1st quarter worth approximately $129,000. Hedge funds and other institutional investors own 77.42% of the company’s stock.
In other news, Chairman Steven A. Kandarian sold 85,683 shares of the business’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $46.93, for a total value of $4,021,103.19. Following the sale, the chairman now owns 585,005 shares of the company’s stock, valued at approximately $27,454,284.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven A. Kandarian sold 42,805 shares of the business’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $47.03, for a total value of $2,013,119.15. Following the completion of the sale, the chairman now directly owns 559,097 shares in the company, valued at approximately $26,294,331.91. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by insiders.
Shares of Metlife stock opened at $48.42 on Friday. Metlife Inc has a 1-year low of $43.09 and a 1-year high of $55.91. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.15 and a current ratio of 0.15. The firm has a market cap of $47.47 billion, a price-to-earnings ratio of 10.76, a price-to-earnings-growth ratio of 0.73 and a beta of 1.22.
Metlife (NYSE:MET) last posted its quarterly earnings data on Wednesday, August 1st. The financial services provider reported $1.30 EPS for the quarter, topping the Zacks’ consensus estimate of $1.17 by $0.13. Metlife had a return on equity of 9.17% and a net margin of 6.12%. The company had revenue of $21.22 billion for the quarter, compared to the consensus estimate of $15.65 billion. During the same quarter in the previous year, the business earned $1.04 EPS. The company’s quarterly revenue was up 36.8% compared to the same quarter last year. research analysts forecast that Metlife Inc will post 5.22 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 13th. Stockholders of record on Monday, August 6th were paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 3.47%. The ex-dividend date was Friday, August 3rd. Metlife’s dividend payout ratio is presently 37.33%.
Several research analysts have recently commented on MET shares. Credit Suisse Group decreased their target price on Metlife from $67.00 to $63.00 and set an “outperform” rating for the company in a research report on Friday, August 17th. Morgan Stanley decreased their target price on Metlife from $53.00 to $52.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 11th. Barclays decreased their target price on Metlife from $60.00 to $57.00 and set an “overweight” rating for the company in a research report on Monday, July 9th. Goldman Sachs Group lowered Metlife from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $55.91 to $61.00 in a research report on Monday, June 4th. Finally, Zacks Investment Research lowered Metlife from a “buy” rating to a “hold” rating in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $54.80.
Metlife Company Profile
MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
Featured Article: Why Dividend Stocks May Be Right for You
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metlife Inc (NYSE:MET).
Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.